- Home
- DAWN vs GLOO Comparison
DAWN vs GLOO Comparison
Compare DAWN & GLOO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- GLOO
- Stock Information
- Founded
- DAWN 2018
- GLOO 2013
- Country
- DAWN United States
- GLOO United States
- Employees
- DAWN N/A
- GLOO N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- GLOO EDP Services
- Sector
- DAWN Health Care
- GLOO Technology
- Exchange
- DAWN Nasdaq
- GLOO Nasdaq
- Market Cap
- DAWN 624.8M
- GLOO 691.4M
- IPO Year
- DAWN 2021
- GLOO 2025
- Fundamental
- Price
- DAWN $9.39
- GLOO $9.02
- Analyst Decision
- DAWN Strong Buy
- GLOO
- Analyst Count
- DAWN 9
- GLOO 0
- Target Price
- DAWN $26.56
- GLOO N/A
- AVG Volume (30 Days)
- DAWN 3.4M
- GLOO 679.7K
- Earning Date
- DAWN 11-04-2025
- GLOO 01-01-0001
- Dividend Yield
- DAWN N/A
- GLOO N/A
- EPS Growth
- DAWN N/A
- GLOO N/A
- EPS
- DAWN N/A
- GLOO N/A
- Revenue
- DAWN $133,672,000.00
- GLOO $41,094,000.00
- Revenue This Year
- DAWN $12.88
- GLOO N/A
- Revenue Next Year
- DAWN $48.27
- GLOO N/A
- P/E Ratio
- DAWN N/A
- GLOO N/A
- Revenue Growth
- DAWN 31.11
- GLOO 9.05
- 52 Week Low
- DAWN $5.64
- GLOO $7.96
- 52 Week High
- DAWN $14.46
- GLOO $9.98
- Technical
- Relative Strength Index (RSI)
- DAWN 60.96
- GLOO N/A
- Support Level
- DAWN $8.16
- GLOO N/A
- Resistance Level
- DAWN $9.77
- GLOO N/A
- Average True Range (ATR)
- DAWN 0.70
- GLOO 0.00
- MACD
- DAWN -0.02
- GLOO 0.00
- Stochastic Oscillator
- DAWN 45.44
- GLOO 0.00
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.